Thymidylate synthase pharmacogenetics in colorectal cancer.

Thymidylate synthase (TS) is an important target for chemotherapy drugs, such as 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (FUDR), oral 5-FU prodrugs (e.g., uracil/tegafur [UFT], S-1, and capecitabine), and other novel folate-based drugs (e.g., raltitrexed, pemetrexed, and nolatrexed). Overexpression of TS is linked to resistance to TS-targeted chemotherapy drugs. Polymorphic tandem repeats located in the TS enhancer region (TSER) have been shown to influence TS expression. Three copies (TSER*3) of the tandem repeat give a 2.6-fold greater in vitro TS expression than 2 copies (TSER*2). A stepwise increase in expression and enzyme activity has been observed with increasing copies of the TSER. Alleles containing 4 (TSER*4), 5 (TSER*5), and 9 (TSER*9) copies of the tandem repeat have also been identified, although the effect of these alleles remains unclear. Preliminary data have suggested that stage III colorectal cancer patients with the TSER*3/TSER*3 genotype do not receive the improvement in survival from adjuvant 5-FU observed in patients with the TSER*3/TSER*2 or TSER*2/TSER*2 genotype. A poor response rate to 5-FU for neoadjuvant rectal or metastatic colorectal disease is also apparent in TSER*3/TSER*3 patients. This has significant clinical implications because TSER*3/TSER*3 occurs in 30% of Caucasian patients. Ethnic variation also exists in the TSER, with Asian populations having significantly higher frequency of TSER*3 than other world populations. Prospective confirmation of the impact of TSER on outcome, after TS-targeted chemotherapy, will define the utility of pharmacogenetics to optimize the selection of 5-FU therapy for colorectal cancer.

[1]  B. Iacopetta,et al.  A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil , 2001, British Journal of Cancer.

[2]  H. McLeod,et al.  Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. , 2001, International journal of oncology.

[3]  J. García-Foncillas,et al.  Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Haller.  Update on chemotherapy for advanced colorectal cancer. , 2001, Oncology.

[5]  R. Goldberg,et al.  Adjuvant chemotherapy for colon cancer , 2001, Current oncology reports.

[6]  H. Saka,et al.  Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.

[7]  H. McLeod,et al.  Novel thymidylate synthase enhancer region alleles in African populations , 2000, Human mutation.

[8]  K. Kawakami,et al.  Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. , 1999, Anticancer research.

[9]  H. McLeod,et al.  Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. , 1999, Genomics.

[10]  F. Maley,et al.  Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Peters,et al.  Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  S. Groshen,et al.  Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Lenz,et al.  Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. , 1997, Cancer letters.

[14]  N. Horie,et al.  Identification of Functional Elements in the Promoter Region of the Human Gene for Thymidylate Synthase and Nuclear Factors That Regulate the Expression of the Gene* , 1997, The Journal of Biological Chemistry.

[15]  C. Allegra,et al.  Identification of in vivo target RNA sequences bound by thymidylate synthase. , 1996, Nucleic acids research.

[16]  A. Jackman,et al.  Effect of Hammerhead Ribozyme against Human Thymidylate Synthase on the Cytotoxicity of Thymidylate Synthase Inhibitors , 1995, Japanese journal of cancer research : Gann.

[17]  P. Johnston,et al.  Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells. , 1995, British Journal of Cancer.

[18]  N. Horie,et al.  Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. , 1995, Cell structure and function.

[19]  P. Johnston,et al.  Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.

[20]  H E Rockette,et al.  The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Johnson.  Posttranscriptional regulation of thymidylate synthase gene expression , 1994, Journal of cellular biochemistry.

[22]  G. Maley,et al.  Identification of an RNA binding site for human thymidylate synthase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Seno,et al.  Regulatory sequences clustered at the 5′ end of the first intron of the human thymidylate synthase gene function in cooperation with the promoter region , 1992, Somatic cell and molecular genetics.

[24]  P. Johnston,et al.  Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. , 1992, Cancer research.

[25]  O. Gotoh,et al.  Structural and functional analysis of the human thymidylate synthase gene. , 1990, The Journal of biological chemistry.

[26]  O. Gotoh,et al.  Human thymidylate synthase gene: isolation of phage clones which cover a functionally active gene and structural analysis of the region upstream from the translation initiation codon. , 1989, Journal of biochemistry.

[27]  S. Altman,et al.  Role in translation of a triple tandemly repeated sequence in the 5'-untranslated region of human thymidylate synthase mRNA. , 1987, Nucleic acids research.

[28]  S. Groshen,et al.  Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy , 2001, The Pharmacogenomics Journal.

[29]  A. Juretić,et al.  Combined modality therapy of rectal cancers. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  S. Groshen,et al.  ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Groshen,et al.  Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.